Macrophage Activation Syndrome
"Macrophage Activation Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serious complication of childhood systemic inflammatory disorders that is thought to be caused by excessive activation and proliferation of T-LYMPHOCYTES and MACROPHAGES. It is seen predominantly in children with systemic onset JUVENILE IDIOPATHIC ARTHRITIS.
| Descriptor ID |
D055501
|
| MeSH Number(s) |
C20.683.515.800
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Macrophage Activation Syndrome".
Below are MeSH descriptors whose meaning is more specific than "Macrophage Activation Syndrome".
This graph shows the total number of publications written about "Macrophage Activation Syndrome" by people in this website by year, and whether "Macrophage Activation Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 9 | 1 | 10 |
| 2018 | 6 | 0 | 6 |
| 2019 | 1 | 0 | 1 |
| 2020 | 7 | 6 | 13 |
| 2021 | 3 | 3 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Macrophage Activation Syndrome" by people in Profiles.
-
Discrimination of COVID-19 From Inflammation-Induced Cytokine Storm Syndromes Using Disease-Related Blood Biomarkers. Arthritis Rheumatol. 2021 10; 73(10):1791-1799.
-
A Case Report of Macrophage Activation Syndrome Complicating Multisystem Inflammatory Syndrome in Children Associated With COVID-19: A Diagnostic Challenge. Clin Pediatr (Phila). 2022 02; 61(2):104-106.
-
Evaluation of the relationship between pentraxin 3 (PTX3) rs2305619 (281A/G) and rs1840680 (1449A/G) polymorphisms and the clinical course of COVID-19. J Med Virol. 2021 Dec; 93(12):6653-6659.
-
Current Understanding of Multisystem Inflammatory Syndrome (MIS-C) Following COVID-19 and Its Distinction from Kawasaki Disease. Curr Rheumatol Rep. 2021 07 03; 23(8):58.
-
Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol Online J. 2021 Jun 29; 19(1):98.
-
Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome. Viruses. 2021 06 03; 13(6).
-
Macrophage Activation Syndrome in a Child with Juvenile Idiopathic Arthritis Secondary to SARS-CoV-2. J Trop Pediatr. 2021 05 17; 67(2).
-
Cytokine storm in severe COVID-19 pneumonia. J Med Virol. 2021 Sep; 93(9):5474-5480.
-
Frequency of Interleukin-6 rs1800795 (-174G/C) and rs1800797 (-597G/A) Polymorphisms in COVID-19 Patients in Turkey Who Develop Macrophage Activation Syndrome. Jpn J Infect Dis. 2021 Nov 22; 74(6):543-548.
-
Diffuse interstitial pneumonia-like/macrophage activation syndrome-like changes in patients with COVID-19 correlate with length of illness. Ann Diagn Pathol. 2021 Aug; 53:151744.